[HTML][HTML] Therapeutic development based on the immunopathogenic mechanisms of psoriasis
Psoriasis, a complex inflammatory autoimmune skin disorder that affects 2–3% of the global
population, is thought to be genetically predetermined and induced by environmental and …
population, is thought to be genetically predetermined and induced by environmental and …
An update review of biosimilars of adalimumab in psoriasis–Bioequivalence and interchangeability
X Zhou, Z Chen, X Bi - Drug Design, Development and Therapy, 2021 - Taylor & Francis
Biologic drugs have revolutionized the treatment of psoriasis and other rheumatological
diseases. In recent years, many biosimilar agents that are highly similar in structure and …
diseases. In recent years, many biosimilar agents that are highly similar in structure and …
[HTML][HTML] The endoribonuclease N4BP1 prevents psoriasis by controlling both keratinocytes proliferation and neutrophil infiltration
C Gou, W Ni, P Ma, F Zhao, Z Wang, R Sun, Y Wu… - Cell Death & …, 2021 - nature.com
Psoriasis is a common chronic skin disease, characterized by abnormal interplay between
hyperproliferative epidermal keratinocytes and self-reactive immune cells with not fully …
hyperproliferative epidermal keratinocytes and self-reactive immune cells with not fully …
Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
A Morita, K Nishikawa, F Yamada… - The Journal of …, 2022 - Wiley Online Library
Based on extrapolation of similar clinical outcomes in rheumatoid arthritis to the originator
infliximab (IFX) in randomized clinical trials, the first biosimilar antibody CT‐P13 was …
infliximab (IFX) in randomized clinical trials, the first biosimilar antibody CT‐P13 was …
A systematic review investigating at what proportion clinical images are shared in prospective randomized controlled trials involving patients with psoriasis and …
S Polesie, F Alinaghi, A Egeberg - Journal of Dermatological …, 2023 - Taylor & Francis
For many patients including those with psoriasis, scientific manuscripts comprising clinical
outcomes including psoriasis area severity index (PASI) and/or physician global assessment …
outcomes including psoriasis area severity index (PASI) and/or physician global assessment …
Biosimilars for the treatment of psoriasis: a systematic review of clinical trials and observational studies
Importance Biosimilars have the potential to reduce costs for the management of moderate-
to-severe psoriasis compared with originators. However, the extrapolation of evidence …
to-severe psoriasis compared with originators. However, the extrapolation of evidence …
[HTML][HTML] Efficacy and safety of HLX03, an adalimumab biosimilar, in patients with moderate-to-severe plaque psoriasis: a randomized, double-blind, phase III study
L Cai, L Li, H Cheng, Y Ding, Z Biao, S Zhang… - Advances in …, 2022 - Springer
Introduction Adalimumab has been used successfully in the treatment of psoriasis. The
objective of the study is to compare the efficacy, safety, and immunogenicity between …
objective of the study is to compare the efficacy, safety, and immunogenicity between …
Cross-switch from etanercept originator to biosimilar SB4 and to GP2015 in patients with chronic plaque psoriasis
S Piaserico, A Conti, F Messina, A Meneguzzo… - BioDrugs, 2021 - Springer
Biosimilars of anti-TNF-α inhibitors have become a valid and usually less expensive
alternative to their originator drugs [1]. Therefore, switching from originator to biosimilar …
alternative to their originator drugs [1]. Therefore, switching from originator to biosimilar …
Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group
FG Demirkan, K Ulu, K Öztürk, ŞG Karadağ… - Expert opinion on …, 2022 - Taylor & Francis
Objectives To review the real-life data, to provide an input to the literature concerning
treatment of juvenile idiopathic arthritis (JIA) with adalimumab (ADL) biosimilar. Method This …
treatment of juvenile idiopathic arthritis (JIA) with adalimumab (ADL) biosimilar. Method This …
Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program “ …
W Owczarek, I Walecka, A Nowakowska… - … in Dermatology and …, 2022 - termedia.pl
Results The mean change in PASI, DLQI, and BSA scores at week 14 was 89.92%, 93.75%
and 90.91%, respectively. By week 14, 83.52% of patients achieved PASI75, 49.45% PASI≥ …
and 90.91%, respectively. By week 14, 83.52% of patients achieved PASI75, 49.45% PASI≥ …